Word
Glucagon receptor
Built from index records dated 2026-10-09 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk How this site works
A third docking point, named in records about compounds designed to act at more than one receptor at the same time.
The third lock, for compounds built to fit several.
How the research records put it
The glucagon receptor is the third receptor targeted by the triple agonists in this class. Retatrutide is reported in its 2023 Lancet trial report as a GIP, GLP-1 and glucagon receptor agonist.[1]
That paragraph is the reference wording, carried unchanged, with the record it came from. The plain sentence above it is this publication speaking, and it carries no citation because it adds nothing the reference wording does not hold.
Where this word turns up
3 entries in this index name this word in its records. None of them are described on this site; all are held back pending review.
It turns up on these group pages: Incretin receptor agonists.
Read next
Where this comes from
The record the reference wording is taken from.